AHCC

(redirected from advanced Hepatocellular Carcinoma)
Category filter:
AcronymDefinition
AHCCActive Hexose Correlated Compound (health food supplement)
AHCCAppaloosa Horse Club of Canada
AHCCAicota Health Care Center
AHCCAspen Hill Christian Church
AHCCAdelaide Hills Country Cottages
AHCCAustin Hills Country Club (Malaysia)
AHCCAssociation of Hawaiian Civic Clubs
AHCCArlington Heights Christian Church (Fort Worth, TX)
AHCCAfter Hours Call Center
AHCCAllan Hancock Community College (Santa Maria, CA)
AHCCAmbulatory Health Care Center
AHCCAlamo Heights Chamber of Commerce (Texas)
AHCCAsylum Hill Congregational Church (Hartford, CT)
AHCCAsylum Hill Congregational Church
AHCCAfghan Hound Club of Canada
AHCCAlbuquerque Hispano Chamber of Commerce
AHCCAnderson Hills Christian Church
AHCCAffordable Health Care Concepts
AHCCAccess to Health Care Coalition
AHCCAfrican Heritage Cultural Center
AHCCArabian Horse Club of Connecticut
AHCCAirway Heights Corrections Center (Washington state)
AHCCAffordable Health Care Consultants
AHCCAd Hoc Copyright Coalition
AHCCAurora Hispanic Chamber of Commerce
AHCCAir-Heating & Cooling Coils
AHCCAnaheim Hills Citizens' Coalition
AHCCadvanced Hepatocellular Carcinoma
AHCCAlternate Host Communications Center (US FEMA)
AHCCAuburn Hills Christian Center
AHCCActivated Hexose-Containing Compound
AHCCActive Hemicellulose Compound
AHCCAd Hoc Constitution Committee
AHCCALHFAM Historic Clothing Committee
AHCCAdvocate Health Care Corporation
AHCCAlexandra Hills Cricket Club
AHCCAirport Heights Community Council
AHCCAdvanstar Health Care Communications
AHCCAmes High Career Center (Ames, Iowa)
AHCCAsynchronous Health Care Communication
AHCCAfrican Holy Christian Church
AHCCAdaptive Hybrid Concurrency Control
AHCCActual HOPE VI Cost Certificate
AHCCAlumni House & Conference Center
AHCCActivated Hexose Correlate Compound
AHCCAllied Health Core Course
AHCCAmerican Hindu Cultural Center
AHCCArizona Hispanic Chamber of Commerce
AHCCArlington Heights Chamber of Commerce
AHCCArkansas Health Care Coalition
AHCCAbbotsford Hospital and Cancer Centre
AHCCArizona Housing Counseling Collaborative
AHCCAtchison Heritage Conference Center
AHCCAlbuquerque Hispanic Chamber of Commerce (New Mexico)
AHCCAlexander Hughes Community Center
AHCCAboriginal Homelessness Committee Caucus (Canada)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Following the US FDA approval, LSK BioPharma will evaluate the safety and efficacy of its rivoceranib in combination with Hengrui's camrelizumab (SHR-1210) in the US in first-line patients with advanced hepatocellular carcinoma (HCC),.
Abou-Alfa, M.D., from Memorial Sloan Kettering Cancer Center in New York City, and colleagues randomized 707 patients with advanced hepatocellular carcinoma in a 2-to-1 ratio to receive cabozantinib or matching placebo.
Crocenzi et al., "Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040," Journal of Clinical Oncology, vol.
Advanced hepatocellular carcinoma (HCC) is one of the most deadly diseases with few systemic therapeutic options.
Xing et al., "Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma," Tumor Biology, vol.
Refractory hypoglycemia controlled by systemic chemotherapy with advanced hepatocellular carcinoma: A case report.
Huang et al., "Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial," Journal of Clinical Oncology, vol.
Sharma, "Refractory Hypoglycemia Presenting as First Manifestation of Advanced Hepatocellular Carcinoma," ACG Case Reports Journal, vol.
Lu et al., "An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma," Oncotarget, vol.
Background: Sorafenib is the only therapy shown to improve overall survival in advanced hepatocellular carcinoma (HCC).
Exelixis will receive $200 million upfront and is eligible to receive regulatory milestones, including $60 million upon approval of cabozantinib in Europe for advanced renal cell carcinoma (RCC) and $50 million for approval in advanced hepatocellular carcinoma (HCC), as well as milestones for potential further indications.
Full browser ?